{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-287048","form_type":"8-K","ticker":"NERV","cik":"0001598646","company_name":"Minerva Neurosciences, Inc.","filed_at":"2025-11-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.874937+00:00","generated_at":"2026-05-16T18:27:37.858673+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Minerva Neurosciences appoints Dr. Inderjit Kaul to board; Kaul led Cobenfy schizophrenia program at BMS","bullets":["Dr. Kaul appointed to Minerva's board (Class II) effective Nov 14, 2025; board size increased to 6.","Received initial option grant of 9,500 shares vesting quarterly over 3 years; $40,000 annual cash retainer.","Consulting agreement: $450/hr for 25-30 hrs/month, six-month term; equity top-ups tied to roluperidone milestones.","Kaul previously SVP Late-Stage Clinical Development at BMS, led Cobenfy development for schizophrenia; currently CMO of Draig Therapeutics.","Appointment follows recent $200M private placement to fund confirmatory Phase 3 trial of roluperidone."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-287048","json":"https://secwatch.observer/filing/0001193125-25-287048.json","markdown":"https://secwatch.observer/filing/0001193125-25-287048.md","text":"https://secwatch.observer/filing/0001193125-25-287048.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1598646/000119312525287048/0001193125-25-287048-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1598646/000119312525287048/d48648d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T18:27:37.858673+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}